GRI Bio Implements 1-for-28 Reverse Stock Split to Meet Nasdaq Listing Requirements
Event summary
- GRI Bio's board approved a 1-for-28 reverse stock split, effective January 23, 2026.
- The split reduces outstanding shares from ~15.02 million to ~536,301, aiming to meet Nasdaq's $1 minimum bid price requirement.
- Trading on a split-adjusted basis begins January 26, 2026 under the same ticker symbol 'GRI' with a new CUSIP number.
- Stockholders holding physical certificates must exchange them for electronic shares or new certificates post-split.
The big picture
GRI Bio's reverse stock split is a strategic move to comply with Nasdaq's minimum bid price requirement, a common challenge for clinical-stage biotech companies with volatile share prices. This action reflects broader trends in the biotech sector where firms balance financial engineering with the need to attract investors during prolonged development phases. The split's success will hinge on whether it stabilizes the stock price while maintaining sufficient liquidity for shareholders.
What we're watching
- Compliance Sustainability
- Whether the reverse stock split will successfully maintain GRI Bio's Nasdaq listing and avoid further regulatory scrutiny.
- Market Reaction
- How investors respond to the reduced share count and the potential impact on liquidity and trading volume.
- Operational Focus
- The pace at which GRI Bio advances its clinical pipeline, particularly GRI-0621 for idiopathic pulmonary fibrosis, amid financial restructuring.
Related topics